Methods |
Randomised trial comparing supplements (branched‐chain amino acids) to no supplements in outpatients with cirrhosis. Geographical location Barcelona, Spain. Paper published 1988. |
Participants |
Inclusion criteria: Cirrhosis (almost all of the patients were Childs B or C). Exclusion criteria: None cited. 49 patients (31 men/18 women , mean age 54). |
Interventions |
Intervention group received nutritional supplement (branched‐chain amino acid‐enriched amino acid supplement [65 gm/d in 300 cc water {2224 kcal, 19.6 gm amino acids with 40% as branched chain‐amino acids}]; Controls did not receive supplement. All participants received 80‐90‐gm protein diet, standard treatment for complications. Duration therapy six months. |
Outcomes |
Mortality, appearance hepatic encephalopathy, bilirubin, triceps skinfold thickness, midarm muscle circumference. |
Category of study |
Supplements/Medical. |
Sample size calculation |
Not reported if done. |
Full paper or abstract only |
Full report. |
Notes |
Number of episodes of hepatic encephalopathy were total; for purposes of meta‐analysis, assumed one per patient. Article in Spanish. Unable to find any contact address or e‐mail for Dr Humbert, so no request sent for further information. |
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Low risk |
Table of random numbers. |
Allocation concealment (selection bias) |
Unclear risk |
No details. |
Blinding (performance bias and detection bias) All outcomes |
High risk |
Not blinded. |
Incomplete outcome data (attrition bias) All outcomes |
Low risk |
Two and four dropouts in treatment and control groups accounted for. |
Selective reporting (reporting bias) |
Low risk |
Mortality and morbidity outcomes reported. |
Other bias |
Unclear risk |
Funder not reported. |
Intent to treat analysis |
Low risk |
Although dropouts noted, denominators in paper were all randomised patients. |
Baseline imbalance? |
Low risk |
No differences identified. |
Early stopping? |
Unclear risk |
No sample size calculation and unknown why stopped. |